Genentech/Curis To Reformulate Basal Cell Carcinoma Topical Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Preliminary Phase I results show histological clearance, but less clinical activity than anticipated with Hedgehog antagonist, Curis says.